Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 10,931

Document Document Title
WO/2017/219935A1
The present invention discloses a biaryl urea RORγt inhibitor, and specifically relates to a biaryl urea derivative, as represented by formula I, with an RORγt inhibiting activity, and a manufacturing method thereof, and a pharmaceutic...  
WO/2017/214725A1
A method of screening a compound or a composition for use in modulating opioid withdrawal symptoms in a mammal. The method comprises the steps of: selecting a group of test animals; separating the group into two subgroups; inducing panne...  
WO/2017/212289A1
The present invention relates to a method of reducing, cleaving and/or coupling at least one C=O, C-O, C=C or C=N bond of a compound, using a reagent comprising a stannyl cation.  
WO/2017/209294A1
According to the present invention, it is possible to safely and easily obtain sulfonimidized aromatic compounds using various substrates and a novel sulfonimidization agent by irradiating, with light in the presence of an oxidizer, a co...  
WO/2017/202273A1
Disclosed in the present invention are a benzyl phenyl ether derivative, a preparation method therefor, and a pharmaceutical composition and uses thereof. Specifically, the present invention relates to a benzyl phenyl ether derivative re...  
WO/2017/197870A1
The present invention belongs to a method for preparing p-carboxybenzene sulfonamide. A method for oxidatively synthesizing p-carboxybenzene sulfonamide by means of oxygen. The method comprises: oxygen is taken as an oxidizing agent, an ...  
WO/2017/199264A1
The present invention provides a novel and commercially viable process with high yield for the preparation of (E)-N-hydroxy-3-(3-phenylsulfamoyl-phenyl)-acrylamide, also known as Belinostat (I). The invention also provides process for pu...  
WO/2017/199103A1
The present disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein ring A, R1, R2, R3, R4, R5, n and p are as defined herein, which are active as modulators of retinoid-related orphan re...  
WO/2017/197670A1
Disclosed in the present application is a method for synthesizing a 1,2-dimethylene cyclobutane chiral compound. The 1,2-dimethylene cyclobutane chiral compound is synthesized from an allenylamine compound in the presence of a rhodium co...  
WO/2017/191000A1
Substituted aromatic sulfonamides of formula (I) pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a di...  
WO/2017/192304A1
The present disclosure is directed to compounds of formula (I): or a pharmaceutically acceptable salt, solvate or solvate of the salt thereof. Compounds of formula (I) are inhibitors of NOX4 and are useful in the treatment of fibrotic di...  
WO/2017/191332A3
A process of forming compounds of formula (I) comprising the steps of addition of an amino compound H2NR to a compound of formula (II) followed by cyclization, isomerization and hydrolysis.  
WO/2017/184604A1
In one aspect, compounds of Formula A, or a pharmaceutically acceptable salt thereof, are featured, or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.  
WO/2017/179018A1
There are provided Tissue Transglutaminase (TG2) inhibitor compounds, and compositions and methods of use thereof for the prevention or treatment of a cancer. Compounds of Formula I, and pharmaceutically acceptable salts thereof, are pro...  
WO/2017/177307A1
Compounds having a structure of Formula I or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R3, R11a, R11b, R11c, R11d, and X, are as defined herein, are provided. Uses of such compounds for modulat...  
WO/2017/170826A1
The purpose of the invention is to provide a compound useful in the prevention or treatment of diabetes, obesity, and conditions related thereto. The present invention relates to an enhancing agent for glucagon-like peptide-1 receptor ac...  
WO/2017/162390A1
New benzenesulfonyl asymmetric ureas are herein disclosed, corresponding to the general formulas (I) –(IV) and pharmaceutically acceptable salts thereof, whose structure and substituents are detailed in the specification. Procedures fo...  
WO/2017/153952A1
The invention is directed to substituted salicylamide derivatives. Specifically, the invention is directed to compounds according to Formula (I): wherein R, R1 and R2 are as defined herein, or a pharmaceutically acceptable salt thereof. ...  
WO/2017/150244A1
In the present invention, a perfluoroalkane sulfonyl imide acid metal salt is produced by reacting a perfluoroalkane sulfonyl halide with an organic base and ammonia or an ammonium halide to obtain a mixture containing "a salt or a compl...  
WO/2017/148318A1
Disclosed are a substituted acrylamide compound and a pharmaceutical composition thereof, the substituted acrylamide compound being a compound of a formula (I), or a crystalline form, pharmaceutically acceptable salt, prodrug, stereoisom...  
WO/2017/133675A1
The present invention relates to a method for preparing a high-purity cyclohexenone long-chain alcohol represented by formula I. The compound represented by formula I is prepared by using metal-mediated Barbier reaction. The method of th...  
WO/2017/135786A1
The present invention relates to a novel amide compound usefully available for the prevention or treatment of a bone disease and the use thereof.  
WO/2017/131221A1
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4a and R4b are as defined in the specification, processes for their preparation, pharmaceutical compositions cont...  
WO/2017/124835A1
The present invention discloses a compound (I) having 1-sulfonamido-4-aryloxy as a basic backbone. A preliminary activity test showed that the compound of the present invention provides excellent interference of a binding of NRF2 by KEAP...  
WO/2017/126851A1
The present invention relates to a method for preparing lithium fluorosulfonylimide and, particularly, provides a method for preparing lithium fluorosulfonylimide from a mixture containing a fluorosulfonylimide inorganic salt, a lithium ...  
WO/2017/124020A1
A polymer composition includes a conductive polymer and at least one stretchability and electrical conductivity (STEC) enhancer, wherein a content of the STEC enhancer in the composition is at least about 1 wt.% of the composition.  
WO/2017/119666A1
The present invention relates to a chiral resolution method for a stereoisomeric mixture, the method comprising a step for mixing a stereoisomeric mixture of a compound, in which an amine group is attached to an asymmetric carbon atom, a...  
WO/2017/112972A1
The invention relates to a method for producing ionic liquids based on bistriflimid anion. In a first stage, a primary aliphatic amine R-NH2 is reacted with triflic anhydride Tf2O so as to form corresponding N-alkylated triflic imid R-NT...  
WO/2017/104589A1
Provided is a method for producing a perfluoroalkylated compound at low cost, safely and with high efficiency. A method for producing a perfluoroalkylated compound, comprising reacting a bis(perfluoroalkanoyl)peroxide with a compound tha...  
WO/2017/106409A1
Disclosed are compounds of Formula A, or a salt thereof, where Q, X, R1 and R2 are as defined herein, which compounds have properties for inhibiting Nav 1.7 ion channels found in peripheral and sympathetic neurons. Also described are pha...  
WO/2017/106820A1
An effective therapeutic agent for the M2 channel comprising sulfonylamide or oxabicyclo structures effective for treating amantadine-resistant influenza A infections, and methods of treating amantadine-resistant influenza A infections t...  
WO/2017/099695A1
N-[(aminosulfonyl)phenyl]-2-(1,2-dihydro-2-oxo-3H-indol-3-yl idene)-hydrazinecarbothioamide derivatives of the following formula (III) for treating cancer and immunological disorders. R5, R6 and R7 are each independently selected from hy...  
WO/2017/088819A1
The present application relates to a preparation method of intermediate compounds with formula II and formula III of a compound (N-{3-[3-(9H-purin-6-yl) pyridin-2-ylamino]-4-chloro-2-fluorophenyl}-3-fluoropropane- 1-sulfonamide) for regu...  
WO/2017/090877A1
The present invention relates to a novel method for preparing lithium bis(fluorosulfonyl)imide and, more specifically, to a method for preparing lithium bis(fluorosulfonyl)imide, capable of simply and economically preparing lithium bis(f...  
WO/2017/085467A1
The present invention relates to a process for producing α-aminosulfonamides. The invention also relates to α-aminosulfonamide compounds, including peptidomimetics that incorporate at least one sulfonamide bond in place of a correspond...  
WO/2017/083971A1
The present disclosure relates to the use of a bioactive compound as an inhibitor of the Wnt/β-Catenin signalling pathway for inhibiting replication of Influenza A virus. The present disclosure also relates to a medicament for inhibitin...  
WO/2017/078149A1
Disclosed is an additive for nonaqueous electrolyte solutions, which contains a disulfonic acid amide compound represented by formula (1). In formula (1), A represents CmH(2m-n)Zn; m represents an integer of 1-6; n represents an integer ...  
WO/2017/079609A1
Cancer is a disease for which there remains a great unmet medical need, and therefore the discovery and development of new antineoplastic agents is critically important. The present invention relates in part to new therapeutic compounds ...  
WO/2017/071410A1
A crystalline form of iodosulfuron-methyl-sodium of formula (I), the crystal preparation process, the analyses of the crystal through various analytical methods, using the crystal to prepare stable agrochemical formulation and the use of...  
WO/2017/070718A4
The invention provides compounds for use as medicaments, which act by inhibiting CYP17A1 and CYP19A1 enzymes. The compounds have particular application in the treatment of cancer especially prostate cancer and breast cancer. The compound...  
WO/2017/070719A3
The invention provides pharmacophores for use in the design, screening and identification of inhibitors of CYP17A1 and CYP19A1 enzymes. A preferred pharmacophore has a spatial arrangement of atoms as shown in the accompanying Figure 1, w...  
WO/2017/070718A1
The invention provides compounds for use as medicaments, which act by inhibiting CYP17A1 and CYP19A1 enzymes. The compounds have particular application in the treatment of cancer especially prostate cancer and breast cancer. The compound...  
WO/2017/070084A1
The disclosed subject matter provides N- hydroxylsulfonamide derivative compounds of formulae (I), (II) or (III) as drawn below, pharmaceutical compositions comprising such compounds, kits comprising such compounds, and methods of using ...  
WO/2017/065495A3
The present invention relates to a compound for inhibiting the secretion of thymic stromal lymphopoietin (TSLP) from mast cells, and a use thereof. It has been confirmed that the compound of the present invention significantly inhibits t...  
WO/2017/065495A2
The present invention relates to a compound for inhibiting the secretion of thymic stromal lymphopoietin (TSLP) from mast cells, and a use thereof. It has been confirmed that the compound of the present invention significantly inhibits t...  
WO/2017/066742A1
Provided herein are novel compounds of Formulae I-III, and methods of using the same to selectively inhibit BACE2.  
WO/2017/049409A1
Disclosed are compounds of general formula (I) that promote readthrough of a premature termination codon (PTC) of an RNA molecule in a translation system, and their use, alone or in combination with other compounds, such as aminoglycosid...  
WO/2017/047572A1
A heat-sensitive recording material obtained by forming a heat-sensitive recording layer, which contains a basic dye and a developer, on a supporting body. The developer is composed of at least one N-substituted amino acid derivative rep...  
WO/2017/049245A2
The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions fu...  
WO/2017/049245A3
The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions fu...  

Matches 1 - 50 out of 10,931